ALLURION TECHNOLOGIES, INC.
No SEC Form 4 filings for $ALUR in the last 30 days.
See all $ALUR insider activity →ALLURION TECHNOLOGIES, INC. (ALUR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers.
ALLURION TECHNOLOGIES, INC. (ALUR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 alur-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 EXECUTION July 21, 2026 RTW Investments, LP 40 10th Avenue, Floor 7 New York, NY 10014 United States Re: 3(a)(9) Exchange Agreement Ladies and Gentlemen: This letter agreement (the “ Agreement ”) confirms the agreement of All
ALLURION TECHNOLOGIES, INC. (ALUR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001964979 false NONE NONE 0001964979 alur:CommonStockParValue00001PerShareMember 2026-07-17 2026-07-17 0001964979 alur:WarrantsToPurchase000378787SharesOfCommonStockEachAtAnExercisePriceOf303750PerShareOfCommonStockMember 2026-07-17 2026-07-17 0001964979 2026-07-17 2026-07-1
Over the past 7 days, alphai's AI scored 1 news story mentioning ALUR (ALLURION TECHNOLOGIES, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ALUR coverage spans corporate actions and financial news.
Leadership changes may affect governance and strategic direction.
The 8-K discloses a share-for-warrant exchange tied to existing secured notes and revenue interest financing, implying potential dilution and capital-structure changes.
Leadership transition with no interim CEO increases execution and governance uncertainty, which can pressure near-term sentiment and valuation multiples.
Board/committee change is a governance event that can affect oversight and future director nominations, but the filing provides no operational or financial rationale.
Board-level governance change may affect committee leadership and near-term oversight, but no operational or financial guidance was provided.
alphai scores every news story that mentions ALUR with an AI model for sentiment and relevance, and aggregates insider trades from ALLURION TECHNOLOGIES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ALLURION TECHNOLOGIES, INC. (ALUR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers.
1 min readALLURION TECHNOLOGIES, INC. (ALUR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 alur-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 EXECUTION July 21, 2026 RTW Investments, LP 40 10th Avenue, Floor 7 New York, NY 10014 United States Re: 3(a)(9) Exchange Agreement Ladies and Gentlemen: This letter agreement (the “ Agreement ”) confirms the agreement of All
4 min readALLURION TECHNOLOGIES, INC. (ALUR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001964979 false NONE NONE 0001964979 alur:CommonStockParValue00001PerShareMember 2026-07-17 2026-07-17 0001964979 alur:WarrantsToPurchase000378787SharesOfCommonStockEachAtAnExercisePriceOf303750PerShareOfCommonStockMember 2026-07-17 2026-07-17 0001964979 2026-07-17 2026-07-1
3 min readALLURION TECHNOLOGIES, INC. (ALUR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001964979 NONE NONE 0001964979 alur:WarrantsToPurchase000378787SharesOfCommonStockEachAtAnExercisePriceOf303750PerShareOfCommonStockMember 2026-06-30 2026-06-30 0001964979 alur:CommonStockParValue00001PerShareMember 2026-06-30 2026-06-30 0001964979 2026-06-30 2026-06-3
2 min readALLURION TECHNOLOGIES, INC. (ALUR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001964979 NONE NONE 0001964979 alur:CommonStockParValue00001PerShareMember 2026-06-24 2026-06-24 0001964979 2026-06-24 2026-06-24 0001964979 alur:WarrantsToPurchase000378787SharesOfCommonStockEachAtAnExercisePriceOf303750PerShareOfCommonStockMember 2026-06-24 2026-06-2
2 min readThe New York Stock Exchange (NYSE) announced it will begin delisting proceedings against Allurion Technologies, Inc. (ALUR) because the company failed to maintain the required average global market capitalization of at least $15,000,000 over a consecutive 30 trading day period. Trading in Allurion's common stock and warrants has been immediately suspended. Allurion Technologies has the right to appeal this decision to a Committee of the Exchange's Board of Directors.
3 min readAllurion Technologies Inc. (ALUR) saw its stock surge over 50% today after the U.S. FDA granted premarket approval for its Allurion Gastric Balloon System, which includes the swallowable Allurion Smart Capsule. This non-surgical weight-loss device offers an alternative to GLP-1 medications and bariatric surgery, targeting a large market of over 80 million Americans. The capsule is designed to be swallowed, filled with fluid, and remain in the stomach for approximately four months, aiding weight loss before naturally passing out of the body.
3 min readAllurion Technologies received FDA premarket approval for its Allurion Gastric Balloon System, an AI-powered solution for weight loss that requires no surgery, endoscopy, or anesthesia. The swallowable balloon remains in the stomach for approximately four months before self-emptying, targeting metabolically healthy weight loss by helping patients lose weight, keep it off, and maintain muscle. This approval marks a significant milestone for Allurion in the U.S. and offers an alternative to GLP-1s and bariatric surgery.
3 min readThe Zacks Medical products industry sees steady demand, but macro headwinds keep growth under pressure in 2025. BSX, PODD, BLFS and ALUR reflect the favorable fundamentals.
6 min readComplaint Seeks to Protect Medtimo's Balloon System Technology and Alleges That Allurion Infringes Three Medtimo Patents
2 min read
